Researchers Use CRISPR To Repair Genetic Defect That Causes Blindness (dispatchtribunal.com)
hypnosec writes: In what has been claimed to be the first use of gene editing technique CRISPR for replacement of a defective gene associated with a sensory disease, researchers have repaired a genetic defect that causes blindness. The research that led to successful editing of defective genes responsible for retinitis pigmentosa (RP) – an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide – was carried out using stem cells derived from a patient's tissue. Published in Scientific Reports, the study paves the way for using CRIPSR therapeutically to treat eye diseases.
"...the study paves the way for using CRISPR therapeutically to treat eye disease."
needs to read "...the study paves the way for using CRISPR therapeutically to treat all diseases and transform the human species."
Curing blindness sounds admirable - but at what cost?
Don't forget the unseen side effects!
The first Google hit on CRISPR side effects is:
http://phys.org/news/2015-10-c...
Write a real methods section next time. It is impossible to tell what went on from that, rendering this report worthless other than as a propaganda tool.
Is it CRISPR or CRIPSR? The summary offers both.
The article you reference does not demonstrate any side effects.
However, it is a valid concern, in that in vitro CRISPR/CAS9 and CRISPR/CPF1 edits has historically hit identical palindromic sequences that happened to be outside the target edit area, since the palindromes in question are only 24 or so base pairs in length. You have to expect that there will be other instances elsewhere in the genome.
If you read the article, the experiment was conducted on pluripotent stem cells created from skin cells taken from the patient, and done in vitro.
The eventual hope in this case is implantation of the in vitro stem cells in order to correct the defect.
This means that any side effects can be avoid by separating the edited cells into individual cells, and then culturing each batch to the point some of the batch can be taken and fully sequenced to verify that the only change in the gene sequences relative to the (fully sequenced) parent organisms genome, is the target gene sequence alone. This would be done before implantation, which would guarantee that the gene sequence causing the disease was the only one impacted by the therapy.
Practically speaking, we have AAVV/AAV-2 techniques -- utilizing Adeno-associated virus vectors, in other words -- that tend to be much more accurate. This is the type of vector that was utilized by the CEO of BioViva, Elizabeth "Liz" Parrish:
https://www.youtube.com/watch?...
Yes witeboi, they can cure your phalitis pigmentosa.
That is... so cool. I thought it was essentially too late for alterations to an adult's DNA to have much effect, but I suppose that depends on what you're changing.
Many disease-causing mutations are beneficial in one copy, problematic with two. The gene for sickle cell anaemia gives heterozygous carriers immunity to malaria, for instance. Ashkenazi have an intelligence-enhancing gene which can also lead to horrific paralysis and death (this one is unusual in that its autosomal dominant, the bad effects are brought on by stress or just by old age, sucks to be smart but also to be watching for the moment your hands start to shake). Point is that gene editing is going to reduce population diversity and will weaken the species even as it strengthens individuals. We should be coming down hard on this stuff in agriculture, or a hundred years from now there will be no cows. To cure eg cystic fibrosis, then yes, I would allow limited use but encourage governments to be very very careful.
CRISPR doesn't target palindromic sequences. It's only hard requirement is that an NGG (for Cas9) be downstream of the target site. Further, the length of the guide sequence (20bp) is sufficient that it will typically hit a unique target. Specificity can be increased by shortening the guide (18bp still works) and by using Cas9 bearing mutations that increase specificity. We're not there yet, but we're really close to actually being able to reliably generate unique edits at any unique sequence in the genome.
However, it is a valid concern, in that in vitro CRISPR/CAS9 and CRISPR/CPF1 edits has historically hit identical palindromic sequences that happened to be outside the target edit area, since the palindromes in question are only 24 or so base pairs in length. You have to expect that there will be other instances elsewhere in the genome.
I guess they need to use a larger CRC.
Sorry, but the length guide is *not* sufficient.
While it's more specific than sequence homology predicts, it's less specific than the laser focus it's portrayed as having.
I understand the need to portray it as being as close to perfect as possible to preserve funding (and the research *should* be funded!), right now, the best method we have of ensuring that off-target mutations do not occur is via post-sequencing.
See these papers regarding "Dammit, I missed!":
New Sequencing Methods Reveal Off-Target Effects of CRISPR/Cas9
https://www.genomeweb.com/sequ...
Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors
http://www.nature.com/nbt/jour...
Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases
http://www.ncbi.nlm.nih.gov/pm...
CRISPR-Cas9 Specificity: Taming Off-target Mutagenesis
http://www.genecopoeia.com/res...
Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells
http://www.nature.com/nmeth/jo...
Quantifying on- and off-target genome editing
http://www.cell.com/trends/bio...
CRISPR/Cas9 Guide
https://www.addgene.org/CRISPR...
Salient quote: "The randomness of NHEJ-mediated DSB repair has important practical implications, because a population of cells expressing Cas9 and a gRNA will result in a diverse array of mutations (for more information, jump to Plan Your Experiment). In most cases, NHEJ gives rise to small InDels in the target DNA which result in in-frame amino acid deletions, insertions, or frameshift mutations leading to premature stop codons within the open reading frame (ORF) of the targeted gene. Ideally, the end result is a loss-of-function mutation within the targeted gene; however, the “strength” of the knock-out phenotype for a given mutant cell is ultimately determined by the amount of residual gene function."
P.S.: And you know as well as I do that the 'P' in "CRISPR" stands for "Palindromic".
Nice article
Nice
Nice article
Interesting
Hello